Juswinder Singh

发表

Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.

Z. Deng, C. Chuaqui, Juswinder Singh, 2004, Journal of medicinal chemistry.

The interaction between phenylalanine rings in proteins

Janet M. Thornton, Juswinder Singh, J. Thornton, 1985 .

Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

C. Chuaqui, Juswinder Singh, Miki N. Newman, 2003 .

Atlas of protein side-chain interactions

J. Thornton, Juswinder Singh, 1992 .

The resurgence of covalent drugs

Adrian Whitty, Juswinder Singh, Thomas A. Baillie, 2011, Nature Reviews Drug Discovery.

Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.

Zhan Deng, Juswinder Singh, Z. Deng, 2005, Journal of medicinal chemistry.

Knowledge-based design of target-focused libraries using protein-ligand interaction constraints.

Zhan Deng, Juswinder Singh, Z. Deng, 2006, Journal of medicinal chemistry.

Targeted covalent drugs of the kinase family.

Juswinder Singh, Juswinder Singh, R. Petter, 2010, Current opinion in chemical biology.

Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma.

Juswinder Singh, R. Petter, R. Pepinsky, 2004, Current topics in medicinal chemistry.

A Novel Small-Molecule Inhibitor of Transforming Growth Factor B Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection

Juswinder Singh, S. Albelda, M. Corbley, 2007 .

Recurrence after Surgical Resection and Prevents Tumor In vivo Mesothelioma Tumor Growth Type I Receptor Kinase ( SM 16 ) Inhibits Murine β Factor A Novel Small-Molecule Inhibitor of Transforming Growth

Juswinder Singh, S. Albelda, M. Corbley, 2007 .

Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,

Juswinder Singh, S. Ponader, M. Nacht, 2011 .

Abstract C189: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations.

Juswinder Singh, M. Nacht, M. Raponi, 2011 .

The Ascension of Targeted Covalent Inhibitors.

Juswinder Singh, 2022, Journal of medicinal chemistry.

The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis.

H. V. van Vlijmen, Juswinder Singh, H. Adkins, 2003, European journal of biochemistry.

A Novel Versatile Strategy for Synthesis of New Series of 4(3H)-Quinazolinone N-Nucleosides.

Juswinder Singh, I. R. Siddiqui, S. Yadav, 2010 .

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Juswinder Singh, M. Nacht, R. Petter, 2013, The Journal of Pharmacology and Experimental Therapeutics.

In vitro propagation studies of virus tolerant citrus rootstock Cleopatra mandarin (citrus reshnii Tanaka)

M. K. Kaul, Juswinder Singh, S. Saxena, 2014 .

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Juswinder Singh, R. T. Sjin, M. Nacht, 2012 .

Identification of a frizzled‐like cysteine rich domain in the extracellular region of developmental receptor tyrosine kinases

Juswinder Singh, J. Saldanha, D. Mahadevan, 1998, Protein science : a publication of the Protein Society.

Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).

Juswinder Singh, Faming Zhang, J. Yingling, 2004, Current opinion in drug discovery & development.

A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection

Juswinder Singh, S. Albelda, M. Corbley, 2007 .

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Juswinder Singh, W. Pao, T. van Dyke, 2013, Cancer discovery.

A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.

Juswinder Singh, S. Albelda, M. Corbley, 2007, Cancer research.

The role of polar interactions in the molecular recognition of CD40L with its receptor CD40

Juswinder Singh, Juswinder Singh, J. Naismith, 1998, Protein science : a publication of the Protein Society.

The Use of Virtual Screening in ALK5 Kinase Inhibitor Discovery and Validation of Orally Active ALK5 Kinase Inhibitors in Oncology

C. Chuaqui, Juswinder Singh, Miki N. Newman, 2008 .

Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.

Juswinder Singh, M. Nacht, L. Qiao, 2013, Journal of medicinal chemistry.

A Kinase‐focused Compound Collection: Compilation and Screening Strategy

Jessica Friedman, Patrick Cullen, Jason Donnelly, 2006, Chemical biology & drug design.

In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Juswinder Singh, M. Nacht, M. Raponi, 2014, Molecular Cancer Therapeutics.

SM16, an Orally Active TGF-&bgr; Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

C. Chuaqui, Juswinder Singh, Miki N. Newman, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

Juswinder Singh, T. Kipps, J. Gabrilove, 2012 .

Intracellular TGF-β Receptor Blockade Abrogates Smad-Dependent Fibroblast Activation In Vitro and In Vivo

Scott Bowes, Serene Josiah, Juswinder Singh, 2006 .

Secondary and Supersecondary Motifs in Protein Structures

Janet M. Thornton, B. L. Sibanda, Bancinyane L. Sibanda, 1992 .

3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists

Herman van Vlijmen, Charles Hammond, Craig Zimmerman, 2002, J. Comput. Aided Mol. Des..

Interleukin 2-inducible T cell kinase (ITK) facilitates efficient egress of HIV-1 by coordinating Gag distribution and actin organization.

Juswinder Singh, H. Akiyama, S. Gummuluru, 2013, Virology.

Differentiation of peptide molecular recognition by phospholipase Cγ‐1 Src homology‐2 domain and a mutant Tyr phosphatase PTP1bC215S

Juswinder Singh, D. Mcnamara, E. Dobrusin, 1995, Protein science : a publication of the Protein Society.

A comparison of three theoretical approaches to the study of side-chain interactions in proteins

John B. O. Mitchell, J. Thornton, Juswinder Singh, 1993 .

Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo.

Scott Bowes, Serene Josiah, Juswinder Singh, 2006, The Journal of investigative dermatology.

Position Specific Interaction Dependent Scoring Technique for Virtual Screening Based on Weighted Protein-Ligand Interaction Fingerprint Profiles

Sangtae Kim, Ravi Nandigam, Claudio Chuaqui, 2009, J. Chem. Inf. Model..

Snail and spider toxins share a similar tertiary structure and ‘cystine motif’

T. Blundell, Juswinder Singh, C. Humblet, 1994, Nature Structural Biology.

Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

Scott Bowes, Serene Josiah, Juswinder Singh, 2003, Bioorganic & medicinal chemistry letters.

A novel database of disulfide patterns and its application to the discovery of distantly related homologs.

Herman W T van Vlijmen, Juswinder Singh, H. V. van Vlijmen, 2004, Journal of molecular biology.

Identification of Potent and Novel α4β1 Antagonists Using in Silico Screening

Herman W. T. van Vlijmen, Juswinder Singh, Juswinder Singh, 2002 .

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.

Juswinder Singh, Juswinder Singh, Hugues Bernard, 2011, Nature chemical biology.

Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-γ1

Juswinder Singh, D. W. Fry, A. McMichael, 1994, Peptides.

Prolonged Inhibition of BCR Signaling and Suppression of B Cell Lymphoma through Irreversible Inhibition of Bruton’s Tyrosine Kinase

Juswinder Singh, Hugues Bernard, M. Nacht, 2008 .

A novel method for the modelling of peptide ligands to their receptors.

J M Thornton, J Saldanha, J. Thornton, 1991, Protein engineering.

SIRIUS. An automated method for the analysis of the preferred packing arrangements between protein groups.

J M Thornton, J. Thornton, Juswinder Singh, 1990, Journal of molecular biology.

Towards an understanding of the arginine-aspartate interaction.

J M Thornton, J. Thornton, Juswinder Singh, 1992, Journal of molecular biology.

Amino/aromatic interactions

John B. O. Mitchell, J. Thornton, Juswinder Singh, 1993, Nature.

Small Molecule Therapeutics In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Juswinder Singh, M. Nacht, M. Raponi, 2014 .

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.

Juswinder Singh, Hugues Bernard, M. Nacht, 2011, Nature chemical biology.